China Sky One Medical, Inc. Exports Sumei Slim Patch to South Korea and Sudan
Medical, Inc. (“China Sky One Medical” or “the Company”) (Nasdaq: CSKI), a
leading fully integrated pharmaceutical company producing
over-the-counter drugs in
announced that its wholly owned subsidiary, Harbin Tian Di Ren Medical Science
and Technology Company, has expanded the sale of its Sumei Slim Patch into
countries and regions.
Following three months of market research, discussions and negotiations,
China Sky One Medical has engaged PAX¡¤Medicare and Lai Li Investment Company
as exclusive sales agents for the Sumei Slim Patch in
respectively. The Slim Patch has passed the necessary examinations required in
both countries and will be available to consumers shortly. China Sky One
Medical’s international sales team, PAX-Medicare and Lai Li Investment Company,
is currently developing a detailed marketing plan that includes sales
projections for the Slim Patch in both
The Sumei Slim Patch is a proprietary weight loss product. Its main
ingredients are extracted from Chinese herbs, which are healthy, natural and
free of harmful side effects. Due to its effectiveness and safety, the Sumei
Slim Patch is one of China Sky One Medical’s best-selling products, and has
received accolades from consumers in
“We are pleased to expand sales of the Sumei Slim Patch into
and
potential,” said Mr.
“It is well known that South Koreans spend money on keeping in shape, and we
expect Sumei Slim Patch to perform well in these countries and create value
for both consumers and shareholders.”
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a
The Company engages in the manufacturing, marketing and distribution of
pharmaceutical, medicinal and diagnostic products. Through its
wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology
Company (“TDR”),
Heilongjiang Tianlong Pharmaceutical, Inc. (“Tianlong”) and Peng Lai Jin
Chuang Pharmaceutical Company (“Jin Chuang”) the Company manufactures and
distributes over-the-counter pharmaceutical products, which make up its major
revenue source. For more information, visit http://www.skyonemedical.com .
Safe Harbor Statement
Certain of the statements made in the press release constitute
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements can be identified by the use
of forward- looking terminology such as “believe,” “expect,” “may,” “will,”
“should,” “project,” “plan,” “seek,” “intend,” or “anticipate” or the negative
thereof or comparable terminology. Such statements typically involve risks and
uncertainties and may include financial projections or information regarding
differ materially from the expectations reflected in such forward-looking
statements as a result of a variety of factors, including the risks associated
with the effect of changing economic conditions in
China
on new product development, variations in new product development, risks
associated with rapid technological change, and the potential of introduced or
undetected flaws and defects in products, and other risk factors detailed in
reports filed with the Securities and Exchange Commission from time to time.
For more information, please contact:
Company Contact:
China Sky One Medical, Inc.
Mr. Yu-Bo Hao, CFO
Tel: +86-451-5399-4069
Email: china_sky_one@yahoo.cn
Investor Relations Contact:
CCG Investor Relations
Mr. Crocker Coulson, President
Tel: +1-646-213-1915
Email: crocker.coulson@ccgir.com
Web: http://www.ccgirasia.com
SOURCE China Sky One Medical, Inc.